Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

Abstract The response rate to obeticholic acid (OCA), a potential therapeutic agent for non-alcoholic fatty liver disease, is limited. This study demonstrated that upregulation of the alternative bile acid synthesis pathway increases the OCA treatment response rate. The hepatic transcriptome and bil...

Full description

Bibliographic Details
Main Authors: Seung Min Lee, Dae Won Jun, Eileen Laurel Yoon, Ju Hee Oh, Yoon Jin Roh, Eun Jeoung Lee, Ji-Hee Shin, Young-Do Nam, Hyun Sung Kim
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Biology Direct
Subjects:
Non-alcoholic fatty liver
Obeticholic acid
Bile acid
Alternative pathway
Biomarker
Microbiome
Online Access:https://doi.org/10.1186/s13062-023-00407-4

Internet

https://doi.org/10.1186/s13062-023-00407-4

Similar Items